MedTrace Logo

Buprenorphine for Late-Life Treatment Resistant Depression

NCT01071538 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-03-09

Study results available
· View outcomes & findings →

Summary

The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.

Conditions

Interventions

DRUG

Buprenorphine

Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Reckitt Benckiser LLC

    collaborator INDUSTRY

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Jordan F Karp, M.D. · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01071538 on ClinicalTrials.gov